OPTEC
International Adds Pandemic 10 Minute Rapid-Test Kits
To PPE
Distribution Network.
CARLSBAD,
CA -- February 9, 2021 -- InvestorsHub NewsWire
-- OPTEC
International, Inc. (OTC
Pink: OPTI),
a
developer of UV and UV-C safety products using related advanced
technologies specific to Personal Protection Equipment (PPE), today
announced the addition of Antigen & Antibody Rapid-Test
Kits with highly accurate results in 10 Minutes to the company's
PPE Inventory for global distribution. The Rapid-Test Kits are
manufactured in the USA and comply with the specific requirements
for Rapid-Testing within the current FDA and CDC
guidelines.
Dr.
Drew Pinsky, OPTEC Senior
Advisory Board Member stated "Currently the Antibody and Antigen Test
Kits are allowed for use by medical professionals or institutions
in the USA. Applications are in the process of being filed with the
FDA for use in the USA by non-medical personnel, whilst outside of
the USA the Kits are allowed for use by non-medical personnel and
individuals by a growing number of countries. OPTEC today started
providing the USA made Antibody & Antigen Kits
to International distributors".
Benefits of using these types of Rapid Tests:
The Antibody
Test is
designed for the presumptive qualitative indication of past or
present infection by the virus.
The IgM/IgG
Antibody Test is a second-generation antibody detection device
designed to maximize antibody detection sensitivity while
maintaining a high level of analytical sensitivity. Key features of
the device include:
Prevalence
Screening – The IgM/IgG Antibody Test can provide presumptive
qualitative results onsite in a matter of minutes and Provides
Positive/Negative Results in 10 minutes or less.
Works
with human whole blood, serum, or plasma sample types
Increased
analytical sensitivity range with hybrid target Antigen
formulation.
Dedicated
sample well for improved incubation and immunobinding
Ideal
low cost & high-volume compliment to nucleic acid or
confirmatory Lab testing
Colored
test indicators for easy & accurate result
interpretation
The Antigen
Test
The Antigen tests are
commonly used in the diagnosis of respiratory pathogens, including
influenza viruses and respiratory syncytial virus. The U.S. Food
and Drug Administration (FDA) has granted emergency use
authorization (EUA) for Antigen tests that can identify the
pandemic.
Antigen tests are
immunoassays that detect the presence of a specific viral Antigen,
which implies current viral infection. Antigen tests are currently
authorized to be performed on nasopharyngeal or nasal swab
specimens placed directly into the assay's extraction buffer or
reagent. The currently authorized Antigen tests are not restricted
to use on persons of a certain age.
Antigen tests are
relatively inexpensive, and most can be used at the point of care.
Most of the currently authorized tests return results in
approximately 10 minutes. Antigen tests are
generally less sensitive than real-time reverse transcription
polymerase chain reaction (RT-PCR) and other nucleic acid
amplification tests (NAATs) for detecting the presence of viral
nucleic acid. However, RT-PCR can detect levels of viral nucleic
acid that cannot be cultured, suggesting that the presence of viral
nucleic acid does not always indicate contagiousness.
Proper interpretation
of both Antigen test results and confirmatory testing when
indicated is important for accurate clinical management of patients
with the suspected pandemic virus or for identification of infected
persons when used for screening.
The clinical
performance of Antigen diagnostic tests largely depends on the
circumstances in which they are used. Both Antigen tests and NAATs
perform best when the person is tested when viral load is generally
highest. They also may be informative in diagnostic testing
situations in which the person has a known exposure to a person
with the pandemic virus.
Important Links:
Regarding Pandemic Testing Requirements.
https://static1.squarespace.com/static/5e433381dd97e66de3df5d89/t/5eb17a3131ddc33eee97d3ce/1588689458805/COVID-19-Tests-Policy+5-4-2020.pdf
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-Antigen
About
OPTEC International, Inc.
With
Locations in Carlsbad and Vista, California,
OPTEC International
is a developer and manufacturer of electronic LED, Ultraviolet (UV)
& UV-C safety products and related advanced technologies and
PPE (Personal Protection Equipment) products. The company's
Safe-Scan product line is being launched at a time when HR
directors and facilities managers are experiencing extreme concern
with respect to keeping environments safe during the global
pandemic crisis and the safe reopening of the U.S. economy. For
more information, visit: www.optecintl.com www.z2o.com
OPTEC International,
Inc. investor relations at: www.optecintl.com/investor
Safe
Harbor Statement: Safe harbor from
liability established by the Private Securities Litigation Reform
Act of 1995. These forward-looking statements generally can be
identified by phrases such as Opti, OPTEC or its management
"believes," "expects," "anticipates," "foresees," "forecasts,"
"estimates" or other words or phrases of similar import. Similarly,
statements herein that describe the Company's business strategy,
outlook, objectives, plans, intentions, or goals also are
forward-looking statements. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking
statements. OPTEC International Inc.
OPTEC
International, Inc.
Investor Relations
Contact:
Andrew
Barwicki
516-662-9461
/ Andrew@barwicki.com
SOURCE: Optec
International, Inc.